CAS: 623152-17-0; 4-((5-(Cyclopropylcarbamoyl)-2-Methylphenyl)Amino)-5-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]Triazine-6-Carboxamide

该化合物是一个化学化合物,主要针对其潜在的治疗应用进行研究,特别是在肿瘤学领域,被归类为小分子抑制剂,具体针对癌症细胞扩散和生存的某些途径;该化合物显示有选择地抑制特定动脉酶,这些酶在各种细胞过程,包括信号传输和细胞分解中起着关键作用;BMS 582949在临床前研究中显示出希望,表明对某些类型肿瘤的功效;其药用动力特性,如吸收,分布,代谢和排泄,对于确定其是否适合临床使用至关重要;此外,安全和毒性特征是研究人员在药物开发过程中评估的关键因素;总的来说,BMS 582949是癌症研究的一个重要领域,正在进行的研究旨在了解其全部潜力和行动机制.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号107-10-8 丙胺 | CAS号623152-11-4 ethyl 4-(5-(cyc...

合成工艺路线路线简述

    📜((4-(5-(Cyclopropylcarbamoyl)-2-Methylphenylamino)-5-Methylpyrrolo[1,2-F][1,2,4]Triazine-6-Carbonyl)(Propyl)Carbamoyloxy)Methyl 2-(4-(Phosphonooxy)Phenyl)Acetate 反应 2191.5H,反应生成 4-[[5-[(环丙基氨基)羰基]-2-甲基苯基]氨基]-5-甲基-N-丙基吡咯并[2,1-F][1,2,4]三嗪-6-甲酰胺
    参考文献: Crystalline Forms Of ((((4-((5-(Cyclopropylcarbamoyl)-2-Methylphenyl)Amino)-5-Methylpyrrolo[2,1-F][1,2,4]Triazin-6-yl)Carbonyl)(Propyl)Carbamoyl)Oxy)Methyl (4-(Phosphonooxy)Phenyl)Acetate,Method Of Preparation And Use Thereof[fr] Formes Cristallines De ((((4-((5-(Cyclopropylcarbamoyl)-2-Méthylphényl)Amino)-5-Méthylpyrrolo[2,1-F][1,2,4]Triazin-6-yl)Carbonyl)(Propyl)Carbamoyl)Oxy)Méthyl (4-(Phosphonooxy)Phényl)Acétate,Procédé D'élaboration Et D'Utilisation
    标题: Crystalline Forms Of ((((4-((5-(Cyclopropylcarbamoyl)-2-Methylphenyl)Amino)-5-Methylpyrrolo[2,1-F][1,2,4]Triazin-6-yl)Carbonyl)(Propyl)Carbamoyl)Oxy)Methyl (4-(Phosphonooxy)Phenyl)Acetate,Method Of Preparation And Use Thereof[fr] Formes Cristallines De ((((4-((5-(Cyclopropylcarbamoyl)-2-Méthylphényl)Amino)-5-Méthylpyrrolo[2,1-F][1,2,4]Triazin-6-yl)Carbonyl)(Propyl)Carbamoyl)Oxy)Méthyl (4-(Phosphonooxy)Phényl)Acétate,Procédé D'élaboration Et D'Utilisation

    海关参考信息

    专利信息


    专利号:US-10906888-B2
    优先权日:2016-07-14
    标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
    发明人:CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
    权利人:PFIZER
    摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-10308615-B2
    优先权日:2015-05-29
    标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
    发明人:CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
    权利人:PFIZER
    摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-2018230127-A1
    优先权日:2015-08-13
    标题 :Bicyclic-Fused Heteroaryl Or Aryl Compounds
    发明人:ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; GAVRIN LORI KRIM; GOLDBERG JOEL ADAM; LEE ARTHUR; LOWE MICHAEL DENNIS; PATNY AKSHAY; PIERCE BETSY SUSAN; SAIAH EDDINE; TRZUPEK JOHN DAVID
    权利人:PFIZER
    摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.

    专利号:US-10316018-B2
    优先权日:2015-08-27
    标题 :Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
    发明人:LEE KATHERINE LIN; ALLAIS CHRISTOPHE PHILIPPE; DEHNHARDT CHRISTOPH MARTIN; GAVRIN LORI KRIM; HAN SEUNGIL; HEPWORTH DAVID; LEE ARTHUR; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; OWEN DAFYDD RHYS; PAPAIOANNOU NIKOLAOS; SAIAH EDDINE; STROHBACH JOSEPH WALTER; TRZUPEK JOHN DAVID; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG
    权利人:PFIZER
    摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Liu C, Lin J, Hynes J, Wu H, Wrobleski ST, Lin S, Dhar TG, Vrudhula VM, Sun JH, Chao S, Zhao R, Wang B, Chen BC, Everlof G, Gesenberg C, Zhang H, Marathe PH, McIntyre KW, Taylor TL, Gillooly K, Shuster DJ, McKinnon M, Dodd JH, Barrish JC, Schieven GL, Leftheris K. Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]t riazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor. J Med Chem. 2015 Sep 22. [Epub ahead of print] doi: 10.1016/j.ejps.2015.05.006. Epub 2015 May 8. doi: 10.1016/j.atherosclerosis.2015.03.039. Epub 2015 Mar 28. doi: 10.1016/j.bmcl.2013.03.022. Epub 2013 Mar 15. doi: 10.3109/1547691X.2012.736427. Epub 2012 Nov 23. doi: 10.1021/jm100540x. doi: 10.1517/13543770902816160.

    合成参考文献


    摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知